Answers are grounded in this paper and cite their sources.
Review reveals mechanisms of T cell exhaustion markers in colorectal cancer, highlighting dual checkpoint inhibition to overcome resistance to anti-PD-1 immunotherapy.
Exhaustion of T cells, characterized by their compromised function and cytokine production, was first discovered in chronic infections and later redefined in the context of immunosuppressed tumor microenvironment (TME). Exhaustion markers include the immune checkpoints PD-1, TIM-3, LAG-3, and TIGIT. Colorectal cancer (CRC), which ranks among the highest in global prevalence, has been associated with exhaustion of T cells. While many trials have focused on anti-PD1 therapeutics in clinical trials, results indicate suboptimal efficacy. A robust approach involved dual blockade of other immune checkpoints together with PD-1. Interestingly, novel exhaustion markers could be used as prognostic markers for the development and progression of CRC. The present work discusses the basics of T cell exhaustion markers and their signaling in CRC. Also, novel combination therapy approaches and challenges in the field are discussed.
No takes yet. Share an insight, caveat, or question.
Zamani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: